Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

623 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Hypertensive response to labetalol in pheochromocytoma].
Enoki N, Satoh Z, Ogata A, Yukioka H, Nishimura K, Fujimori M. Enoki N, et al. Among authors: ogata a. Masui. 1984 Sep;33(9):1008-11. Masui. 1984. PMID: 6512967 Japanese. No abstract available.
Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
Ogata A, Amano K, Dobashi H, Inoo M, Ishii T, Kasama T, Kawai S, Kawakami A, Koike T, Miyahara H, Miyamoto T, Munakata Y, Murasawa A, Nishimoto N, Ogawa N, Ojima T, Sano H, Shi K, Shono E, Suematsu E, Takahashi H, Tanaka Y, Tsukamoto H, Nomura A; MUSASHI Study Investigators. Ogata A, et al. J Rheumatol. 2015 May;42(5):799-809. doi: 10.3899/jrheum.140665. Epub 2015 Apr 1. J Rheumatol. 2015. PMID: 25834203 Clinical Trial.
A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S; SHINOBI study group. Ogata A, et al. Mod Rheumatol. 2018 Jan;28(1):76-84. doi: 10.1080/14397595.2017.1332507. Epub 2017 Jun 16. Mod Rheumatol. 2018. PMID: 28622048 Free article. Clinical Trial.
Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S, Yamakawa R; SHINOBI Study Group. Ogata A, et al. Mod Rheumatol. 2019 Sep;29(5):767-774. doi: 10.1080/14397595.2018.1533514. Epub 2018 Dec 14. Mod Rheumatol. 2019. PMID: 30299202 Free article. Clinical Trial.
Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis.
Ogata A, Atsumi T, Fukuda T, Hirabayashi Y, Inaba M, Ishiguro N, Kai M, Kawabata D, Kida D, Kohsaka H, Matsumura R, Minota S, Mukai M, Sumida T, Takasugi K, Tamaki S, Takeuchi T, Ueda A, Yamamoto K, Yamanaka H, Yoshifuji H, Nomura A; Musashi Study Investigators. Ogata A, et al. Arthritis Care Res (Hoboken). 2015 Oct;67(10):1354-62. doi: 10.1002/acr.22598. Arthritis Care Res (Hoboken). 2015. PMID: 25832859 Free PMC article. Clinical Trial.
623 results